X4 Pharmaceuticals, Inc
No enriched coverage for $XFOR in the last 7 days.
No SEC Form 4 filings for $XFOR in the last 30 days.
See all $XFOR insider activity →X4 Pharmaceuticals (Nasdaq: XFOR) said it issued inducement equity awards effective July 6, 2026 to new employees under its 2019 Inducement Equity Incentive Plan. The grants total options for 750,000 shares, with a $4.03 exercise price, 10-year term, and 4-year vesting (25% after 12 months, then monthly).
X4 Pharmaceuticals, Inc (XFOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. xfor-20260630 0001501697 FALSE 0001501697 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
X4 Pharmaceuticals (Nasdaq: XFOR) said it appointed Kelly Gold to its board effective July 1, 2026. She will be an independent director and Audit Committee member. X4 noted she is CFO of CAMP4 Therapeutics (Nasdaq: CAMP) and has prior Biogen experience. The company said it aims to advance mavorixafor toward potential approval and commercialization.
Recent XFOR coverage spans financial news and corporate actions.
Routine equity inducement grant that can modestly increase dilution but is not a fundamental operating update.
Board expansion and a new audit-committee director appointment is a governance/oversight update, not an operational or financial guidance change.
Board-level CFO appointment signals strengthened financial oversight as X4 advances mavorixafor toward potential approval/commercialization.
Equity inducement grants add dilution/overhang considerations but are typically non-fundamental; the key tradable detail is the strike/vesting structure.
The filing shows an insider sale of approximately 16,961 shares valued at $72,820.41, scheduled for May 12, 2026. This could reflect personal liquidity needs or insider sentiment but does not necessarily indicate a negative outlook on the company's fundamentals.
alphai scores every news story that mentions XFOR with an AI model for sentiment and relevance, and aggregates insider trades from X4 Pharmaceuticals, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
X4 Pharmaceuticals (Nasdaq: XFOR) said it issued inducement equity awards effective July 6, 2026 to new employees under its 2019 Inducement Equity Incentive Plan. The grants total options for 750,000 shares, with a $4.03 exercise price, 10-year term, and 4-year vesting (25% after 12 months, then monthly).
2 min readX4 Pharmaceuticals, Inc (XFOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. xfor-20260630 0001501697 FALSE 0001501697 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readX4 Pharmaceuticals (Nasdaq: XFOR) said it appointed Kelly Gold to its board effective July 1, 2026. She will be an independent director and Audit Committee member. X4 noted she is CFO of CAMP4 Therapeutics (Nasdaq: CAMP) and has prior Biogen experience. The company said it aims to advance mavorixafor toward potential approval and commercialization.
2 min readX4 Pharmaceuticals (Nasdaq: XFOR) said it issued inducement equity awards effective May 29, 2026 to new employees under its 2019 Inducement Equity Incentive Plan. The awards total options for 160,000 shares, with a $4.31 exercise price and a 10-year term. Options vest over four years, subject to continued employment, per Nasdaq Rule 5635(c)(4).
3 min readX4 Pharmaceuticals, Inc. (XFOR) has filed a Form 144 with the SEC, indicating a proposed sale of 16,961 shares of common stock by an unnamed person for an aggregate market value of $72,820.41. The securities were acquired on May 11, 2026, through Restricted Stock Unit Vesting. The sale is expected to occur on May 12, 2026, via Morgan Stanley Smith Barney LLC on NASDAQ.
2 min readX4 Pharmaceuticals is seeking shareholder approval for several key proposals at its virtual 2026 annual meeting on May 11, 2026. These include the election of three Class III directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and the approval of an amended 2017 Equity Incentive Plan to add 1,500,000 shares for employee and director awards. Additionally, shareholders will cast a non-binding advisory vote on executive compensation.
2 min readX4 Pharmaceuticals is at a critical juncture as it focuses on the commercial launch of its lead drug, Mavorixafor (Xolremdi), amidst a unique market environment where the biotech sector is decoupled from broader market optimism. Investors are closely monitoring the therapy's adoption for rare diseases, revenue performance, financial health, and pipeline development to determine the company's long-term valuation and future trajectory. The success of Xolremdi's rollout is considered a defining moment for the company's financials and investor sentiment.
4 min readX4 Pharmaceuticals announced it issued inducement awards to new employees under its 2019 Inducement Equity Incentive Plan, effective January 30, 2026. These awards consist of options to purchase 20,000 shares of X4's common stock at an exercise price of $3.70 per share, granted as a material inducement for their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over a four-year period, with 25% vesting after 12 months and the remainder monthly over the subsequent 36 months, contingent on continued employment.
2 min readBOSTON, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- X4 Pharmaceuticals ( NASDAQ:XFOR ) ( "X4" or the "Company" ) , a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced underwritten public offering of 52,844,000 shares of ...
2 min readBOSTON, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- X4 Pharmaceuticals ( Nasdaq: XFOR ) ( "X4" or the "Company" ) , a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced underwritten public offering of 52,844,000 shares of ...
2 min read
